Cortechs.ai, a leader in AI-based neuroimaging and prostate imaging, announced the successful closing of an oversubscribed Series C funding round led by VILAS Ventures, with participation from existing investor Genting Berhad.
This funding, which exceeded the hard cap, will support Cortechs.ai's mission to advance medical imaging technology, expand its product suite, and enhance its market reach.
The company aims to accelerate the rollout of new features, broaden its commercial footprint, and continue research and development efforts. Cortechs.ai's flagship products include NeuroQuant, crucial for early diagnosis of neurodegenerative diseases like Alzheimer's, and OnQ Prostate, a tool for prostate cancer detection.
CEO Kyle Frye expressed enthusiasm about the investor response, highlighting the importance of AI-powered tools in improving diagnostic confidence and patient outcomes. He noted VILAS Ventures' expertise in healthcare technology as a key factor in their partnership.
Daniel Livschutz, Managing Director of VILAS Ventures, emphasized Cortechs.ai's leadership in AI-driven medical imaging and expressed excitement about the company's potential to address gaps in neuroimaging and cancer detection.
Dato' Sri Tan Kong Han, COO of Genting Berhad, reiterated their commitment to Cortechs.ai's journey and the transformative potential of its advanced imaging solutions.